Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: results of a randomised phase III intergroup study initiated by the AIO and AGMT (ML18147)

被引：0
|
作者：
Greil, R. [1 ]
Arnold, D. [2 ]
Hegewisch-Becker, S.
Freier, W.
Steffens, C. -C. [3 ]
Bertram, M.
Schlichting, C. [4 ]
Andel, J. [5 ]
Taylor, M. [6 ]
Makrutzki, M. [7 ]
Kubicka, S. [8 ]
机构：
[1] Paracelsus Med Univ, Salzburg, Austria
[2] UCCH, Hubertus Wald Tumor Ctr, Hamburg, Germany
[3] MVZ Haematol Onkol Klin Dr Hancken, Stade, Germany
[4] Diakoniekrankenhaus gGmbH, Rotenburg, Germany
[5] LKH Steyr, Steyr, Austria
[6] Genentech Inc, Epidemiol Patient Reported Outcomes & Healthcare, San Francisco, CA 94080 USA
[7] F Hoffmann La Roche & Cie AG, Basel, Switzerland
[8] Kleiskliniken Reutlingen GmbH, Med Klin 1, Reutlingen, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：254 / 254
页数：1
相关论文
共 50 条
  • [21] Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy
    Zhou, Yu-Wen
    Long, Yi-Xiu
    Liu, Xia
    Liu, Ji-Yan
    Qiu, Meng
    FUTURE ONCOLOGY, 2022, 18 (22) : 2453 - 2464
  • [22] Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
    Cybulska-Stopa, Bozena
    Lugowska, Iwona
    Wisniowski, Rafal
    Domagala-Haduch, Malgorzata
    Rajczykowski, Marcin
    Piejko, Karolina
    Bar-Letkiewicz, Ilona
    Suwinski, Rafal
    Regulski, Krzysztof
    Mackiewicz, Jacek
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2020, 24 (01): : 34 - 41
  • [23] Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
    Okines, A.
    Del Puerto, O.
    Cunningham, D.
    Chau, I.
    Van Cutsem, E.
    Saltz, L.
    Cassidy, J.
    BRITISH JOURNAL OF CANCER, 2009, 101 (07) : 1033 - 1038
  • [24] Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
    A Okines
    O del Puerto
    D Cunningham
    I Chau
    E Van Cutsem
    L Saltz
    J Cassidy
    British Journal of Cancer, 2009, 101 : 1033 - 1038
  • [25] Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab
    Bousahba, A.
    Behourah, Z.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
    Yong Sang Hong
    Jeeyun Lee
    Kyu-pyo Kim
    Jae-Lyun Lee
    Young Suk Park
    Joon Oh Park
    Se Hoon Park
    Sun Young Kim
    Ji Yeon Baek
    Jee Hyun Kim
    Keun-Wook Lee
    Tae-You Kim
    Tae Won Kim
    Investigational New Drugs, 2013, 31 : 183 - 191
  • [27] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
    Hong, Yong Sang
    Lee, Jeeyun
    Kim, Kyu-pyo
    Lee, Jae-Lyun
    Park, Young Suk
    Park, Joon Oh
    Park, Se Hoon
    Kim, Sun Young
    Baek, Ji Yeon
    Kim, Jee Hyun
    Lee, Keun-Wook
    Kim, Tae-You
    Kim, Tae Won
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 183 - 191
  • [28] Prognostic Value of the Combination of Circulating Tumor Cells Plus KRAS in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab
    Sastre, Javier
    Vidaurreta, Marta
    Gomez, Auxiliadora
    Rivera, Fernando
    Massuti, Bartomeu
    Reboredo Lopez, Margarita
    Abad, Albert
    Gallen, Manuel
    Benavides, Manuel
    Aranda, Enrique
    Diaz Rubio, Eduardo
    CLINICAL COLORECTAL CANCER, 2013, 12 (04) : 280 - 286
  • [29] Cost-effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer
    Li, Yulian
    Hu, Min
    Zhang, Zhe
    Chu, Mingming
    Xu, Rufu
    Liu, Lulu
    Dong, Wenxing
    Yang, Mengmeng
    Zhang, Rong
    CANCER MEDICINE, 2024, 13 (01):
  • [30] Induction treatment in first-line with chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer: Results from the gercor-DREAM phase III study
    Tournigand, Christophe
    Scheithauer, Werner
    Samson, Benoit
    Lledo, Gerard
    Viret, Frederic
    Andre, Thierry
    Ramee, Jean Francois
    Tubiana-Mathieu, Nicole
    Dauba, Jerome
    Dupuis, Olivier
    Rinaldi, Yves
    Mabro, May
    Aucoin, Nathalie
    Khalil, Ahmed
    Latreille, Jean
    Louvet, Christophe
    Brusquant, David
    Bonnetain, Franck
    Chibaudel, Benoist
    De Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
12345